WaveMan
WaveMan · Company
LCTX · Lineage Cell Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LCTX Lineage Cell Therapeutics (LCTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000876343
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
62
13F, latest reported quarter

Lineage Cell Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Lineage Cell Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Culley Brian M
President and CEO
BUY
2026-03-12 SEC
15,000
$24.4K
-37.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Nov 21, 2024.
  • -2.1% median (+0.1% mean) 90-day return after 4 previous buys.
  • The trade is 5.9% of the 255,516 shares held after it.
  • No other insider bought within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Culley Brian M bought about $24.4K of LCTX on Mar 12, 2026, the largest insider purchase at the company since 2025; 62 funds added in the latest 13F quarter.
BROADWOOD CAPITAL INC
Director
BUY
2025-01-28 SECtraded 2025-01-27
7,894,737
$6.0M
+66.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.9% of the 49,560,992 shares held after it.
  • No other insider bought within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BROADWOOD CAPITAL INC bought about $6.0M of LCTX on Jan 27, 2025; 62 funds added in the latest 13F quarter.
Howe Jill Ann
Chief Financial Officer
BUY
2024-11-26 SEC
15,000
$8.8K
+75.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 16, 2024.
  • The trade is 58.8% of the 25,500 shares held after it.
  • 3 other insiders bought within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Howe Jill Ann bought about $8.8K of LCTX on Nov 26, 2024; 3 other insiders bought within 30 days and 62 funds added in the latest 13F quarter.
Samuel George A. III
General Counsel
BUY
2024-11-26 SEC
15,000
$9.0K
+75.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 67.6% of the 22,184 shares held after it.
  • 3 other insiders bought within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Samuel George A. III bought about $9.0K of LCTX on Nov 26, 2024; 3 other insiders bought within 30 days and 62 funds added in the latest 13F quarter.
Mulroy Michael H.
Director
BUY
2024-11-25 SECtraded 2024-11-22
40,000
$22.8K
+63.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 24, 2022.
  • The trade is 13.4% of the 298,555 shares held after it.
  • 3 other insiders bought within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mulroy Michael H. bought about $22.8K of LCTX on Nov 22, 2024; 3 other insiders bought within 30 days and 62 funds added in the latest 13F quarter.
21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 16 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
62 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
+53.2% year over year
more than 77% of Pharma & Biotech
Margin
-436.5% net margin
below 76% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
13.6% of the float short (float per yahoo 2026-10-27) · 16.8 days to cover · settled 2026-10-15
more than 73% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LCTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.7%12M
-45%-23%-1%+20%2025-102025-122026-022026-042026-062026-082026-10 2026-03-12 · Culley Brian M bought $24.4K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LCTX: institutional holders (13F)

13F holdings, latest reported quarter
BROADWOOD CAPITAL INC
49,560,992 sh
$64.9M
BlackRock, Inc.
13,186,895 sh
$17.3M
VANGUARD CAPITAL MANAGEMENT LLC
9,054,918 sh
$11.9M
Defender Capital, LLC.
6,598,899 sh
$8.6M
GEODE CAPITAL MANAGEMENT, LLC
5,299,457 sh
$6.9M

Congress trades in LCTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LCTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LCTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$289.5K position · as of 2026-06-30
0.2%
iShares Micro-Cap ETF
$808.5K position · as of 2026-06-30
0.1%
1290 VT Micro Cap Portfolio
$54.2K position · as of 2026-06-30
0.0%
iShares Biotechnology ETF
$1.7M position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$2.3M position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$21.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Not applicable
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.1M
$6.3M
$992.1K
-5%
n/a
2024
$2.5M
$706.5K
$1.1M
-72%
n/a
2023
$2.9M
$2.2M
$936.7K
-38%
n/a
2022
$2.4M
-$135.4K
$1.2M
-34%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 62 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LCTX financials

Revenue growth
+53.2%
XBRL, annual
Net margin
-436.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$13.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-246.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$24.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-59.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-32.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-30.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-9.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$14.6M$9.5M$8.9M$14.7M
Gross profitn/an/a$8.3M$14.0M
Operating income-$36.6M-$21.5M-$24.7M-$22.5M
Net income-$63.5M-$18.6M-$21.5M-$26.3M
EPS (diluted)-0.28-0.09-0.12-0.15
Operating cash flow-$18.9M-$23.1M-$28.6M$1.1M
Cash$40.8M$45.8M$35.4M$11.4M
SEC XBRL, fiscal years, as known on 2026-10-28

LCTX Stock Sonar score 4/7 axes

Find similar shapesCompare

LCTX ranks highest on growth (77th percentile) and profitability (58th), and lowest on risk and compliance (17th), among Pharma & Biotech peers.

Profitability
58
Inputs
  • Return on equity-59.0% · 49 pct, sector of 545
  • Return on assets-32.7% · 58 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-30.1% · 67 pct, sector of 576
Growth
77
Inputs
  • Revenue growth, YoY+53.2% · 77 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
52
Inputs
  • Funds adding, latest quarter62 · 52 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+13.6% · 28 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+30.6% · 7 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies